ARCA Biopharma Inc (NASDAQ:ABIO) and Oruka Therapeutics have entered into a definitive agreement to combine the companies in an all-stock transaction.
Oruka Therapeutics is a privately held biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis.
The resulting entity will focus on advancing Oruka’s pipeline, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor).
Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics Inc and trade on Nasdaq under ...